Phibro Animal Health (NASDAQ:PAHC) Upgraded to Overweight at JPMorgan Chase & Co.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) was upgraded by investment analysts at JPMorgan Chase & Co. from a "neutral" rating to an "overweight" rating in a report issued on Monday, Marketbeat Ratings reports. The firm currently has a $35.00 price objective on the stock, up from their prior price objective of $25.00. JPMorgan Chase & Co.'s price objective indicates a potential upside of 17.06% from the company's current price.

Several other equities research analysts have also issued reports on PAHC. Wall Street Zen raised Phibro Animal Health from a "hold" rating to a "buy" rating in a research note on Friday, May 9th. Morgan Stanley set a $26.00 price target on Phibro Animal Health and gave the company an "equal weight" rating in a report on Wednesday, June 25th. BNP Paribas upgraded Phibro Animal Health to a "hold" rating in a report on Monday, June 16th. Finally, BNP Paribas Exane upgraded Phibro Animal Health from an "underperform" rating to a "neutral" rating and set a $24.00 price target on the stock in a report on Monday, June 16th. Two analysts have rated the stock with a sell rating, three have assigned a hold rating and two have given a buy rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $24.40.

Phibro Animal Health Price Performance

Phibro Animal Health stock traded up $1.90 during midday trading on Monday, hitting $29.90. 557,250 shares of the company's stock were exchanged, compared to its average volume of 215,503. Phibro Animal Health has a 52-week low of $16.16 and a 52-week high of $30.74. The stock has a 50-day moving average price of $23.60 and a two-hundred day moving average price of $22.14. The company has a debt-to-equity ratio of 2.67, a quick ratio of 1.23 and a current ratio of 2.91. The company has a market cap of $1.21 billion, a P/E ratio of 38.33, a PEG ratio of 0.47 and a beta of 0.75.

Phibro Animal Health (NASDAQ:PAHC - Get Free Report) last posted its earnings results on Wednesday, May 7th. The company reported $0.63 EPS for the quarter, topping the consensus estimate of $0.52 by $0.11. Phibro Animal Health had a return on equity of 30.51% and a net margin of 2.68%. The business had revenue of $347.80 million during the quarter, compared to analysts' expectations of $352.41 million. On average, equities research analysts forecast that Phibro Animal Health will post 1.95 earnings per share for the current year.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Bank of New York Mellon Corp grew its stake in shares of Phibro Animal Health by 2.9% in the 4th quarter. Bank of New York Mellon Corp now owns 272,632 shares of the company's stock worth $5,725,000 after buying an additional 7,747 shares during the last quarter. Charles Schwab Investment Management Inc. grew its stake in shares of Phibro Animal Health by 8.3% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 290,656 shares of the company's stock worth $6,104,000 after buying an additional 22,263 shares during the last quarter. Raymond James Financial Inc. purchased a new stake in shares of Phibro Animal Health in the 4th quarter worth approximately $1,103,000. Amundi grew its stake in shares of Phibro Animal Health by 185.5% in the 4th quarter. Amundi now owns 9,855 shares of the company's stock worth $212,000 after buying an additional 6,403 shares during the last quarter. Finally, Globeflex Capital L P lifted its position in Phibro Animal Health by 0.8% in the 4th quarter. Globeflex Capital L P now owns 206,595 shares of the company's stock valued at $4,338,000 after acquiring an additional 1,700 shares in the last quarter. Hedge funds and other institutional investors own 99.34% of the company's stock.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.